Distinguished in Acute Lymphoblastic Leukemia (ALL)

James A. Whitlock

Toronto, ON, CA 
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

James Whitlock practices in Toronto, Canada. Mr. Whitlock is rated as a Distinguished expert by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Langerhans Cell Histiocytosis, Acute Lymphoblastic Leukemia (ALL), Reticulohistiocytoma, and Histiocytosis.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 27 articles in the study of Acute Lymphoblastic Leukemia (ALL).

Gender
Male

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

53 Total Publications

Assessing the Impact of u-link.care: Implementation of a Pediatric Cancer Clinical Trials Finder Website to Improve Healthcare Provider Knowledge and Identify Barriers to Enrollment.
Assessing the Impact of u-link.care: Implementation of a Pediatric Cancer Clinical Trials Finder Website to Improve Healthcare Provider Knowledge and Identify Barriers to Enrollment.
Journal: Pediatric blood & cancer
Published: January 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Whitlock's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile